Compare RGEN & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | CRL |
|---|---|---|
| Founded | 1981 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 10.8B |
| IPO Year | 1995 | 1999 |
| Metric | RGEN | CRL |
|---|---|---|
| Price | $166.73 | $277.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $167.67 | ★ $198.27 |
| AVG Volume (30 Days) | ★ 920.0K | 810.0K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 286.96 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | $141,236,000.00 | ★ $1,857,601,000.00 |
| Revenue This Year | $14.30 | N/A |
| Revenue Next Year | $14.52 | $3.04 |
| P/E Ratio | $687.71 | ★ N/A |
| Revenue Growth | ★ 35.10 | 10.48 |
| 52 Week Low | $100.99 | $144.26 |
| 52 Week High | $188.73 | $303.31 |
| Indicator | RGEN | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 46.76 |
| Support Level | $156.65 | $215.89 |
| Resistance Level | $167.74 | $303.31 |
| Average True Range (ATR) | 6.66 | 7.38 |
| MACD | -2.82 | -4.41 |
| Stochastic Oscillator | 8.96 | 1.81 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.